{"id":391534,"date":"2014-10-06T00:00:00","date_gmt":"2014-10-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcoron1014-biopharma-renal-cell-carcinoma-pharmacor-g7-2014\/"},"modified":"2026-03-31T09:04:35","modified_gmt":"2026-03-31T09:04:35","slug":"pcoron1014-biopharma-renal-cell-carcinoma-pharmacor-g7-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcoron1014-biopharma-renal-cell-carcinoma-pharmacor-g7-2014\/","title":{"rendered":"Renal Cell Carcinoma | Pharmacor | G7 | 2014"},"content":{"rendered":"<p>Renal cell carcinoma (RCC) is a disease characterized by significant unmet need and, thus, opportunity. Its incidence is increasing in the major pharmaceutical markets, and many patients with early-stage disease suffer a recurrence. Moreover, the current therapies used to treat stage IV RCC can increase progression-free survival but have limited impact on prolonging overall survival. Interviewed experts are enthusiastic about the promise of an emerging class of drugs for RCC: immune checkpoint inhibitors.<\/p>\n<p><strong>Note: In April 2015, the RCC market was updated to reflect changes in our market assumptions for sorafenib (Bayer HealthCare\/Onyx Pharmaceuticals\u2019 Nexavar).<\/strong><\/p>\n<p>\u00a0<\/p>\n","protected":false},"template":"","class_list":["post-391534","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-renal-cell-carcinoma","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391534\/revisions"}],"predecessor-version":[{"id":394657,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391534\/revisions\/394657"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}